A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Sarcoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Clovis-001
- 22 Aug 2019 Planned number of patients changed from 55 to 70.
- 22 Aug 2019 Status changed from active, no longer recruiting to recruiting.
- 05 Aug 2019 Status changed from recruiting to active, no longer recruiting.